sarpogrelate has been researched along with Arterial Occlusive Diseases in 4 studies
sarpogrelate: structure given in first source
Arterial Occlusive Diseases: Pathological processes which result in the partial or complete obstruction of ARTERIES. They are characterized by greatly reduced or absence of blood flow through these vessels. They are also known as arterial insufficiency.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Forearm blood flow (FBF) and leg blood flow (LBF) responses to reactive hyperemia (RH) and sublingual administration of nitroglycerin (NTG) were measured using strain-gauge plethysmography." | 5.12 | Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease. ( Chayama, K; Goto, C; Higashi, Y; Miyazaki, M; Orihashi, K; Sanada, H; Sueda, T; Yoshizumi, M, 2007) |
| "Sarpogrelate is a selective 5-hydroxytryptamine (5-HT) receptor subtype 2A antagonist which blocks 5-HT induced platelet aggregation and proliferation of vascular smooth muscle cells." | 2.80 | Prospective Randomized Study of Sarpogrelate Versus Clopidogrel-based Dual Antiplatelet Therapies in Patients Undergoing Femoropopliteal Arterial Endovascular Interventions: Preliminary Results. ( Chen, YX; Gu, YQ; Hu, HJ; Li, XQ; Liu, CW; Song, XJ; Tian, HY; Wang, WD; Zhao, JC, 2015) |
| "Ticlopidine was significantly effective only at 100 mg/kg p." | 1.28 | Effect of (+/-)-2-(dimethylamino)-1-[[o-(m-methoxyphenethyl)phenoxy] methyl]ethyl hydrogen succinate on experimental models of peripheral obstructive disease. ( Hara, H; Kitajima, A; Shimada, H; Tamao, Y, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, YX | 1 |
| Wang, WD | 1 |
| Song, XJ | 1 |
| Gu, YQ | 1 |
| Tian, HY | 1 |
| Hu, HJ | 1 |
| Zhao, JC | 1 |
| Li, XQ | 1 |
| Liu, CW | 1 |
| Nishihira, K | 1 |
| Yamashita, A | 1 |
| Tanaka, N | 1 |
| Kawamoto, R | 1 |
| Imamura, T | 1 |
| Yamamoto, R | 1 |
| Eto, T | 1 |
| Asada, Y | 1 |
| Miyazaki, M | 1 |
| Higashi, Y | 1 |
| Goto, C | 1 |
| Chayama, K | 1 |
| Yoshizumi, M | 1 |
| Sanada, H | 1 |
| Orihashi, K | 1 |
| Sueda, T | 1 |
| Hara, H | 1 |
| Shimada, H | 1 |
| Kitajima, A | 1 |
| Tamao, Y | 1 |
2 trials available for sarpogrelate and Arterial Occlusive Diseases
| Article | Year |
|---|---|
Prospective Randomized Study of Sarpogrelate Versus Clopidogrel-based Dual Antiplatelet Therapies in Patients Undergoing Femoropopliteal Arterial Endovascular Interventions: Preliminary Results.
Topics: Aged; Arterial Occlusive Diseases; Clopidogrel; Female; Fibrinolytic Agents; Humans; Kaplan-Meier Es | 2015 |
Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Arterial Occlusive Diseases; Biomarkers; Endothelium, | 2007 |
2 other studies available for sarpogrelate and Arterial Occlusive Diseases
| Article | Year |
|---|---|
Inhibition of 5-hydroxytryptamine receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery.
Topics: Animals; Arterial Occlusive Diseases; Catheterization; Disease Models, Animal; Femoral Artery; Fibri | 2006 |
Effect of (+/-)-2-(dimethylamino)-1-[[o-(m-methoxyphenethyl)phenoxy] methyl]ethyl hydrogen succinate on experimental models of peripheral obstructive disease.
Topics: Animals; Arterial Occlusive Diseases; Carrageenan; Fibrinolytic Agents; Infarction; Lauric Acids; Ma | 1991 |